LaunchTrends®: Lemtrada (US) is a four-wave syndicated report series that specifically tracks the introduction of Genzyme’s Lemtrada (alemtuzumab), a potent, intravenous disease-modifying therapy (DMT) approved for the treatment of relapsing forms of multiple sclerosis (MS). This report series is based on primary research data collected at one month, three months, six months, and one year post-commercial availability of Lemtrada. Along with awareness and sources of familiarity, the reports assess U.S. neurologists’ trial, adoption, and use of Lemtrada, including anticipated future trends. The reports also provide information on product perceptions, satisfaction, obstacles to use, drivers of prescribing, patient types, displacement of competitors, Genzyme’s promotional efforts, and benchmarking against other previously launched MS agents.

Questions Answered:

  • Genzyme launched Lemtrada in the U.S. market as a treatment for relapsing forms of MS in December 2014. What is neurologists’ level of awareness and familiarity with Lemtrada over the course of the following year?
  •  Lemtrada enters an increasingly crowded MS market with ten branded DMT options, four of which have entered in the past five years. What are the perceived clinical advantages and disadvantages of Lemtrada compared with other marketed agents used to treat MS? How is the trial and adoption of Lemtrada tracking compared with other recent product launches in the MS market?
  • Because of its safety profile, Lemtrada’s U.S. label recommends that it should generally be reserved for later-line use in the treatment of relapsing forms of MS. Where do neurologists expect Lemtrada to fit in the MS treatment algorithm? What are the current prescribing trends among DMTs, and how do neurologists anticipate they will change over the next six months?
  •  Lemtrada is Sanofi/Genzyme’s second entrant into the MS market, following the companies’ 2012 launch of Aubagio (teriflunomide). What promotional messages and activities are Genzyme employing in support of the Lemtrada launch?


Markets covered: United States.

Primary research: 74 neurologists surveyed per report Wave; 10 qualitative interviews with a subset of survey respondents.

Indication coverage: Relapsing-remitting MS.

Table of contents

  • Multiple Sclerosis - Emerging Therapies - Lemtrada Launch Tracking Wave 2 (US)
    • Key Findings
      • Awareness and Perceptions of Lemtrada
      • Current Lemtrada Trial and Use
      • Lemtrada Positioning in the Competitive Landscape
      • Anticipated Lemtrada Trial and Use
    • Benchmarking Lemtrada Launch Success vs. MS Analogs
      • Prescriber and Nonprescriber Profiles
        • Lemtrada: Select Prescriber and Nonprescriber Profile Differences
      • Lemtrada Awareness and Perceptions
        • Unaided and Aided Awareness of Lemtrada
          • Aided Awareness of Lemtrada
        • Familiarity with Lemtrada
          • Awareness of Lemtrada Indication*
          • Awareness of Lemtrada Administration*
          • Awareness of Lemtrada Dosing Interval*
        • Sources of Familiarity with Lemtrada
          • Initial Reaction to and Interest in Lemtrada
            • Initial Reaction to and Interest in Learning More About Lemtrada
            • Lemtrada Product Profile
            • Initial Reaction to Lemtrada
            • Interest Level in Lemtrada
          • Impressions of Lemtrada
            • Open-End Responses: Lemtrada Information Requiring Additional Education
            • Uniqueness of Lemtrada vs. Currently Available Treatments
            • Lemtrada Risk-Benefit Profile Balance
            • Qualitative Interview Follow-Ups
            • Unaided Lemtrada Advantages
            • Unaided Lemtrada Disadvantages
            • Open-End Responses: Unaided Advantages of Lemtrada
            • Open-End Responses: Unaided Disdvantages of Lemtrada
            • Qualitative Interview Follow-Ups
            • Clinical Interchangeability of Lemtrada and DMT Brands
            • Statement Agreement Regarding Lemtrada
            • Statement Agreement Regarding Lemtrada
            • Lemtrada Statement Agreement: Wave over Wave
          • Prescriber and Nonprescriber Profiles
            • Lemtrada: Prescriber and Nonprescriber Profile Differences
            • Differences Between Prescriber and Nonprescriber Profiles
        • Lemtrada Trial and Use
          • Willingness to Prescribe Lemtrada
            • Lemtrada Trial
            • Impact of Lemtrada Attributes on Willingness to Prescribe: Wave over Wave
            • Lemtrada Attribute Impact on Willingness to Prescribe
            • Lemtrada Attribute Impact on Willingness to Prescribe
            • Qualitative Interview Follow-Ups
            • Qualitative Interview Follow-Ups
            • Physician Quotes on Impact of Lemtrada Attributes on Willingness to Prescribe
          • Number of Patients Currently Receiving Lemtrada
            • Mean Lemtrada Patient Volume Among Lemtrada Prescribers
            • Prescribed Lemtrada as Part of a Clinical Trial
            • Current Lemtrada Status
            • Lemtrada Prescribing by Disease Classification Among Current Prescribers
            • Physician Quotes on Lemtrada Prescribing by Disease Classification
            • Qualitative Interview Follow-Ups
            • Lemtrada Patient Origination
            • Qualitative Interview Follow-Ups
            • Number of DMTs Used Prior to Lemtrada
            • Course of Lemtrada Treatment Among Current Prescribers
            • Severity of Infusion-Associated Reactions to Lemtrada
            • Percentage of Physicians Receiving Patient Inquiries for Lemtrada in the Past Month
            • Action Based on Specific Lemtrada Patient Requests
            • Qualitative Interview Follow-Ups
            • Percentage of Patients on Lemtrada Seen for Follow Up
            • Response to Lemtrada Treatment
          • Reasons for Not Yet Prescribing Lemtrada
            • Anticipated Lemtrada Prescribing Timeframe Among Nonprescribers
          • Anticipated Lemtrada Use
            • Anticipated RR-MS DMT Treatment Rate: Next Six Months
            • Lemtrada Prescriber Base: Current, Next Six Months, and Ever
            • Potential Peak Share* for Lemtrada
            • Potential Peak Share for Lemtrada: Prescribers vs. Nonprescribers
            • Characteristics of Lemtrada Candidates
            • Qualitative Interview Follow-Ups
          • Lemtrada Performance on Key Attributes
            • Lemtrada Performance Ratings and DMT Choice Attribute Importance Ratings
            • Lemtrada Performance Ratings and DMT Choice Attribute Importance Ratings
            • Overall Lemtrada Satisfaction
            • Open-End Responses: Reasons for High Satisfaction Rating with Lemtrada
            • Open-End Responses: Reasons for Low Satisfaction Rating with Lemtrada
        • Effectiveness of Face-to-Face Detailing for Lemtrada
          • Lemtrada Sales Representative Frequency and Reach
            • Sales Representative Detailing Reach
            • DMT Detailing Frequency Among All Surveyed Neurologists
          • Satisfaction with Lemtrada Sales Representative
            • Satisfaction Rating for Lemtrada Sales Representative Quality Attributes
            • Qualitative Interview Follow-Ups
          • Lemtrada Message Recall
            • Topics Discussed with the Lemtrada Sales Representative*
            • Topics Discussed with the Lemtrada Sales Representative*
        • Methodology
          • Significance Testing in This Study
        • Appendix
          • Primary Market Research
            • Years in Practice Postresidency (percentage of neurologists)
            • U.S. Region of Practice (percentage of neurologists)
            • Practice Location (percentage of neurologists)
            • Practice Setting (percentage of neurologists)
            • Practice Demographics: Prescribers vs. Nonprescribers
            • MS Patient Volume Under Personal Management in Past Year
            • Patient Volume by MS Disease Classification: Prescribers vs. Nonprescribers
          • Additional Information
            • Likely Actions Taken Upon Lemtrada Request
            • Likely Scenario Upon Referral
            • Open End-Responses: Recent Changes in Management/Treatment of MS Patients
            • Qualitative Interview Follow-Ups
            • DMT Treatment Rate Among RR-MS Patients
            • Current Brand Share Among DMT-Treated RR-MS Patients (percentage of DMT-treated RR-MS patients)
            • Last 10 New DMT Prescriptions for RR-MS Patients (percentage of DMT prescriptions)
            • Last 10 Switch DMT Prescriptions for RR-MS Patients (percentage of DMT prescriptions)
            • Lemtrada REMS Program Enrollment Status
            • Enrollment Process Rating
            • Physician Quotes on Lemtrada REMS Program
            • Perception of Managed Care Approval Process Among Lemtrada Prescribers
            • Open-End Responses: Reasons That the Managed Care Approval Process Was Difficult and Time-Consuming
            • Managed Care Requirements for Prescribing Lemtrada*
            • Most Common DMT Failures Requested by MCOs*
            • Percentage of Lemtrada Prescriptions Denied to…
            • Value of Genzyme’s Support Activities for Lemtrada
            • MS Market Background
            • DMTs Indicated for the Treatment of Relapsing Forms of MS in the United States
            • MS Market News: Lemtrada Launch
            • Report Abbreviations
            • Objectives
          • Open-End Responses: Respondent Feedback

      Author(s): John Crowley

      John leads DRG’s Infectious, Niche, & Rare Diseases team and manages the market research portfolio across niche and rare diseases, anti-infectives, and vaccines. Prior to his current role, he was a Director on the team overseeing syndicated and custom work on niche and rare disease markets, as well as atopic dermatitis content in DRG’s Dermatology portfolio. He also served as a DRG analyst in the neurology space, focused mainly on the multiple sclerosis market. John holds a Ph.D. from the University of Massachusetts Medical School and a Bachelor’s degree from Worcester Polytechnic Institute.

      Related Reports

      Multiple Sclerosis - Landscape & Forecast - Disease Landscape & Forecast

      The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will c...

      View Details

      Multiple Sclerosis | Disease Landscape and Forecast | G7 | 2020

      The maturing yet highly lucrative market for multiple sclerosis (MS) disease-modifying therapies (DMTs) will continue to fragment as new entrants drive further shifts in a complicated treatment alg...

      View Details

      Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis (US)

      Three disease-modifying therapies (DMTs)—EMD Serono’s Mavenclad, Novartis’s Mayzent, and Biogen’s Vumerity—joined the crowded U.S. multiple sclerosis (MS) market just...

      View Details

      Multiple Sclerosis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Multiple Sclerosis 2020 – Main Report Dashboard (US)

      With more than a dozen immunomodulatory disease-modifying therapies (DMTs) available to treat multiple sclerosis (MS) and more in the pipeline, the treatment journey for U.S. MS patients continues...

      View Details